Neda Arghand - Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran
Somayeh Reiisi - Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran

Backgrounds: Antimicrobial peptides (AMPs), are essential components of the immune defenseof multicellular organisms and are currently being developed as antimicrobial and antitumordrugs. Lactoferricin-B (LfcinB) is an antimicrobial peptide that has cytotoxic activity againstcancer cells. Studies have shown that Lactoferricin-B or its derivatives can inhibit tumor growthin vitro and in vivo. Thus, aim of this study is improving the approach for the identification ofpotential peptide molecule for GSTP۱ targeting through bioinformatics analysis.Materials and Methods: Lactoferricin-B sequence submits to AntiCP server for predict anddesign of newly anticancer peptides. The ۲D and ۳D structures of these peptides were drawnwith Protean (DNAstar software), Phyre۲ and I-TASSER respectively. Furthermore, anticancerproperty for each peptide expected with iACP software. The ۳D structures of peptides weredocked with the GSTP۱ using docking server HDOCK and the peptide with the maximumbinding energy value was identified.Results: AntiCP server predicts >۳۵۰ peptides with anticancer property. Peptides with highSVM score were selected. Anticancer activity of new design peptides showed ۹۹% anticancerspecificity. Result revealed that among ۳۵۰ peptides were virtually screened ۴۵ peptides showedgreater than ۹۹% anticancer property and among these peptidesFKCRRWQWRMKKLGAPSIWCVRR identified as potential sequence for GSTP۱ ligand.Conclusion: Our results indicated that the probability of successful production of new anticancerpeptide derived of Lactoferricin-B. These outcomes based on in silico analysis may be used incancer therapy or vaccine design. Therefore, new designed peptide can be used as potentialinhibitor agent in for GSTP۱ against cancer.

Anticancer peptide, Lactoferricin B, Bioinformatics, GSTP۱